Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study.
about
Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Efficacy and safety of canagli ...... k, open-label, phase IV study.
@en
Efficacy and safety of canagli ...... k, open-label, phase IV study.
@nl
type
label
Efficacy and safety of canagli ...... k, open-label, phase IV study.
@en
Efficacy and safety of canagli ...... k, open-label, phase IV study.
@nl
prefLabel
Efficacy and safety of canagli ...... k, open-label, phase IV study.
@en
Efficacy and safety of canagli ...... k, open-label, phase IV study.
@nl
P2093
P2860
P356
P1476
Efficacy and safety of canagli ...... k, open-label, phase IV study.
@en
P2093
Kazuoki Kondo
Makiko Otsuka
Nobuko Maruyama
Nobuya Inagaki
Shin-Ichi Harashima
Yutaka Kawaguchi
P2860
P304
P356
10.1111/DOM.13267
P577
2018-03-24T00:00:00Z